[go: up one dir, main page]

AR031117A1 - Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica - Google Patents

Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica

Info

Publication number
AR031117A1
AR031117A1 ARP010103573A ARP010103573A AR031117A1 AR 031117 A1 AR031117 A1 AR 031117A1 AR P010103573 A ARP010103573 A AR P010103573A AR P010103573 A ARP010103573 A AR P010103573A AR 031117 A1 AR031117 A1 AR 031117A1
Authority
AR
Argentina
Prior art keywords
biliar
lipase
preparation
pharmaceutical combination
biliar acid
Prior art date
Application number
ARP010103573A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR031117A1 publication Critical patent/AR031117A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de un inhibidor de lipasa y de un secuestrante de ácido biliar que es para la preparacion de un medicamento para la prevencion y tratamiento de las enfermedades que se asocian con niveles elevados de colesterol plasmático; en especial al uso de un inhibidor de lipasa, por ejemplo, orlistat, y un secuestrante de ácido biliar aceptable para uso farmacéutico para el tratamiento de enfermedades que se relacionan con los niveles elevados de colesterol plasmático; y una combinacion farmacéutica.
ARP010103573A 2000-07-28 2001-07-26 Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica AR031117A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00116392 2000-07-28

Publications (1)

Publication Number Publication Date
AR031117A1 true AR031117A1 (es) 2003-09-10

Family

ID=8169383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103573A AR031117A1 (es) 2000-07-28 2001-07-26 Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica

Country Status (17)

Country Link
US (3) US6562329B2 (es)
EP (1) EP1307263B1 (es)
JP (2) JP4772264B2 (es)
KR (1) KR100556324B1 (es)
CN (1) CN1261094C (es)
AR (1) AR031117A1 (es)
AT (1) ATE293477T1 (es)
AU (2) AU2001289696B2 (es)
BR (1) BR0112800A (es)
CA (1) CA2416900C (es)
DE (1) DE60110232T2 (es)
DK (1) DK1307263T3 (es)
ES (1) ES2240516T3 (es)
MX (1) MXPA03000694A (es)
PT (1) PT1307263E (es)
WO (1) WO2002009814A2 (es)
ZA (1) ZA200300454B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
CA2454732C (en) * 2001-07-30 2010-07-20 Mitsubishi Pharma Corporation Drugs for ameliorating postcibal hyperglycemia
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
CN103027896B (zh) * 2005-09-15 2016-01-20 基酶有限公司 胺聚合物的小袋制剂
US8067402B2 (en) * 2005-12-12 2011-11-29 Allaccem, Inc. Methods and systems for coating an oral surface
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
ITRM20060204A1 (it) 2006-04-10 2007-10-11 Vincenzo Savica Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
EP2125026B1 (en) 2007-02-21 2014-09-24 AllAccem, Inc. Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
CN101791296B (zh) * 2010-01-17 2012-08-29 山东新时代药业有限公司 一种奥利司他片剂及其制备方法
PL2568827T3 (pl) * 2010-05-14 2018-10-31 Omega Pharma Innovation & Development Nv Kompozycja do redukowania wchłaniania tłuszczu przyjmowanego z pokarmem
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
KR102271821B1 (ko) * 2020-12-18 2021-07-01 주식회사 엔테로바이옴 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물
WO2022140261A1 (en) * 2020-12-22 2022-06-30 Ambys Medicines, Inc. Biliary delivery methods, compositions and kits for use therein
CN113057340B (zh) * 2021-04-29 2024-01-19 南京邮电大学 一种菌菇膳食纤维改性方法
WO2023023939A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4161534B1 (en) * 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
WO1997023210A1 (en) * 1995-12-26 1997-07-03 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
KR20010079636A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
KR20010079635A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
ATE293477T1 (de) * 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren

Also Published As

Publication number Publication date
CN1444496A (zh) 2003-09-24
DE60110232D1 (de) 2005-05-25
PT1307263E (pt) 2005-08-31
WO2002009814A3 (en) 2002-04-18
JP2004505066A (ja) 2004-02-19
US6562329B2 (en) 2003-05-13
ZA200300454B (en) 2004-04-16
EP1307263A2 (en) 2003-05-07
KR100556324B1 (ko) 2006-03-03
CN1261094C (zh) 2006-06-28
EP1307263B1 (en) 2005-04-20
MXPA03000694A (es) 2003-06-04
CA2416900A1 (en) 2002-02-07
US20060189574A1 (en) 2006-08-24
KR20030069978A (ko) 2003-08-27
US20020042395A1 (en) 2002-04-11
WO2002009814A2 (en) 2002-02-07
ES2240516T3 (es) 2005-10-16
BR0112800A (pt) 2003-07-01
DK1307263T3 (da) 2005-08-22
JP2009108062A (ja) 2009-05-21
AU8969601A (en) 2002-02-13
JP4772264B2 (ja) 2011-09-14
DE60110232T2 (de) 2006-01-19
CA2416900C (en) 2007-07-03
AU2001289696B2 (en) 2006-07-06
US20030138396A1 (en) 2003-07-24
ATE293477T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
AR031117A1 (es) Uso de inhibidores de lipasa y secuestrantes de acido biliar para la preparacion de un medicamento, dicho inhibidor de lipasa y secuestrante de acido biliar y combinacion farmaceutica
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de ''kit'', el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
ID22746A (id) Senyawa-senyawa baru
ES2181614T3 (es) Sulfonilfenilheterociclos sustituidos como inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
MA28102A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
AR003415A1 (es) Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
GT200100201A (es) Derivados de pirazol para el tratamiento der enfermedades viricas.
DE60233261D1 (de) Inhibitoren von humanem adam-10
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
ATE319715T1 (de) Antikonvulsive pseudofructopyranose sulfamate
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DE60026491D1 (de) Melagatran zur behandlung von entzündungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure